Overview
Pain is a multidimensional sensory and emotional experience that is important for our survival, but once pain becomes chronic it is no longer beneficial and, instead, becomes a disorder in and of itself. Chronic pain remains one of our nation’s most significant healthcare problems due to a limited understanding of the underlying genetic and environmental factors. There are three main objectives of our lab’s research in this area:
- To determine the factors that put some people, but not others, at risk for maladaptive chronic pain conditions. To achieve this objective, we study genetic, biological, and environmental factors associated with the initial onset of pain as well as its severity and duration. In addition, we are beginning to study factors associated with patient-centered outcomes, which may have the power to predict optimal management strategies for different individuals.
- To elucidate the mechanism(s) whereby genetic, biological, and environmental factors drive chronic pain. To achieve this objective, we integrate molecular genetics, animal models, and clinical epidemiologic measures in order to reveal pathogenic processes that are unique to as well as common across a particular condition or individual(s). This line of inquiry will provide novel targets for the development of individualized therapeutics for the management of chronic pain.
- To improve pharmacologic management of pain. To achieve this objective, we conduct pre-clinical studies to test the efficacy of new compounds and to optimize the efficacy of existing compounds in patient-relevant animal models.
Current Appointments & Affiliations
Associate Professor in Anesthesiology
·
2019 - Present
Anesthesiology,
Clinical Science Departments
Associate Professor in Pharmacology and Cancer Biology
·
2017 - Present
Pharmacology & Cancer Biology,
Basic Science Departments
Recent Publications
Thermally Driven Release of Oxycodone from Poly(ester urea) Thin Films by Printed Microheaters for Transdermal Delivery.
Journal Article ACS Appl Mater Interfaces · December 17, 2025 Opioids are widely considered to be one of the most effective pain management strategies, but current prescription and distribution models have resulted in high rates of misuse, addiction, and overdose. An alternative to the systemic delivery of opioids is ... Full text Link to item CitePreclinical perspectives on disorders of the temporomandibular joint: Tracing the past, navigating the present, and shaping the future.
Journal Article J Pain · November 2025 Temporomandibular disorders (TMDs) are complex conditions characterized by orofacial pain and dysfunction, affecting a significant portion of the population. TMDs may involve joint and/or muscle pain, dysfunction (e.g., noise, limited or altered jaw moveme ... Full text Open Access Link to item CiteVestibulodynia presentation is differentiated by the presence of additional chronic primary pain conditions.
Journal Article J Pain · August 2025 Vestibulodynia (VBD) is a common chronic primary pain condition (CPPC) defined by the presence of recurrent vulvovaginal pain with no obvious root cause. As many as 3 in 4 women with VBD may have co-occurring CPPCs, such as episodic migraine, fibromyalgia, ... Full text Link to item CiteRecent Grants
Pharmacological Sciences Training Program
Inst. Training Prgm or CMEPreceptor · Awarded by National Institutes of Health · 2025 - 2030Neuro-immune modulation of pain in health and disease
ResearchCo Investigator · Awarded by National Institute of Dental and Craniofacial Research · 2022 - 2027Identification and validation of LPA/LPAR signaling in temporomandibular disorder pain
ResearchCo-Principal Investigator · Awarded by National Institutes of Health · 2024 - 2027View All Grants
Education, Training & Certifications
University of Georgia ·
2003
Ph.D.